Pam Swiggard

Ms. Swiggard is an accomplished pharmaceutical executive in global regulatory affairs and quality assurance with more than 21 years of experience in operations, clinical research and project management for a broad range of therapeutic areas across development and commercial assets.

Ms. Swiggard previously served as Vice President, Regulatory Affairs at Galera Therapeutics Inc., where she led global strategy for regulatory affairs and provided guidance for product development. Prior to Galera, Ms. Swiggard worked in a variety of leadership roles including Vice President of Regulatory Affairs and Quality Assurance at Zynerba Pharmaceuticals and Fibrocell, Inc. (merged with Castle Creek Biosciences) and Vice President of Regulatory Affairs and Project Management of Trevena, Inc. Previously, Ms. Swiggard served in positions of increasing responsibility in regulatory affairs at Endo Pharmaceuticals, Inc., and for Wyeth Pharmaceuticals that was acquired by Pfizer, Inc. in 2009. Ms. Swiggard earned a B.S. in Microbiology from The Pennsylvania State University and a M.S. in Regulatory Affairs/Quality Assurance from Temple University.